Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

The Valens Company Inc. VLNS.TO TSX

Toronto Stock Exchan • Healthcare • Drug Manufacturers - Specialty & Generic • CA • CAD

SharesGrow Score
30/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

The Valens Company Inc. (VLNS.TO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $1.01. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $78M, +37569.2%/yr average growth. Net income is $49M (loss), growing at -98.2%/yr. Net profit margin is -62.7% (negative). Gross margin is 22.1% (-16.7 pp trend).

Balance sheet: total debt is $15M against $259M equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 1.97 (strong liquidity). Debt-to-assets is 4.5%. Total assets: $345M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 14/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

VLNS.TO SharesGrow Score Overview

37/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 14/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VLNS.TO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
VLNS.TO: +37569.2%/yr revenue is, -98.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet VLNS.TO: Debt-to-Equity (D/E) ratio 0.06 (conservative), Current ratio is 1.97 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
14/100
VLNS.TO: Gross margin is 22.1% (-16.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 14/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
VLNS.TO: Net profit margin is -62.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.76-3.79
Volume57.43K
Avg Volume (30D)130.04K
Beta (1Y)0.00
Share Statistics
EPS (TTM)-1.15
Shares Outstanding$42.52M
IPO Date2020-04-16
Employees445
CEOJeffrey Fallows CFA
Financial Highlights & Ratios
Revenue (TTM)$78.18M
Gross Profit$17.24M
EBITDA$-40.28M
Net Income$-49.03M
Operating Income$-53.99M
Total Cash$30.42M
Total Debt$15.38M
Net Debt$-670K
Total Assets$344.68M
Price / Earnings (P/E)-0.9
Analyst Forecast
Company Info
CountryCA
ExchangeToronto Stock Exchan
CurrencyCAD
ISINCA91914P6030

Price Chart

Track all markets on TradingView
VLNS.TO
The Valens Company Inc. ↗  ·  Toronto Stock Exchan
Healthcare • Drug Manufacturers - Specialty & Generic
0.76 52WK RANGE 3.79

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message